Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of Response-guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-Negative Breast Cancer (NeoSTAR)

Next Previous
Trial Profile

A Phase 2 Study of Response-guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-Negative Breast Cancer (NeoSTAR)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Sacituzumab govitecan (Primary) ; Anthracyclines; Carboplatin; Cyclophosphamide; Docetaxel; Taxanes
  • Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; Male breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use
  • Acronyms NeoSTAR

Most Recent Events

  • 29 May 2025 According to a Parker Hughes Institute media release, the results form this trial will be presented at the ASCO 2025 meeting.
  • 11 Dec 2023 Primary results (n=50) of efficacy and feasibility of Sacituzumab govitecan , published in the Annals of Oncology
  • 09 Dec 2023 Planned number of patients changed from 260 to 145, as per Trial design, presented at the 46th Annual San Antonio Breast Cancer Symposium

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top